Active surveillance of small kidney masses is a safe and effective alternative to immediate surgery, with similar overall and cancer specific survival rates, according to a study published in the November issue of the urology journal BJUI.
The technique is primarily used to treat elderly patients who have complex health issues or decline surgery. But researchers from the Department of Urology at Churchill Hospital, Oxford, UK, say that the results of their study suggest that active surveillance could safely be extended to other selected patients.
“The incidence of kidney cancer has been increasing in Europe and the USA since the 1980s and the use of more sophisticated imaging techniques means that smaller masses of less than 4cm are being picked up at earlier stages” says lead author Dr Nilay Patel.
“This has led to an increased rate of surgery for small kidney masses, but the benefits of this remain unclear. Conflicting reports on improvements in death rates for kidney cancer over the last few years suggest that increased detection may not necessarily be improving survival rates for patients with smaller tumours inside their kidney.”
A total of 202 patients with 234 small renal masses of less than 4cms inside their kidney – classified as T1a – were identified.
Ninety were managed with partial nephrectomy (where only the diseased part of the kidney is removed), 41 with a radical nephrectomy (where the entire kidney is removed) and 71 with active surveillance (where patients are monitored for disease progression).
Key findings included:
Over a median follow-up of 34 months, the mean growth rate of the kidney masses in patients who were under active surveillance was 0.21cm. However, 53 per cent of the small renal masses in these patients showed negative or zero growth.
No statistically significant differences were observed in overall and cancer-specific survival rates for patients who were under active surveillance or received partial or radical nephrectomy.
The overall survival rates were 83 per cent for active surveillance, 80 per cent for radical nephrectomy and 90 per cent for partial nephrectomy.
The cancer specific survival rates were 99 per cent for active surveillance, 93 per cent for radical nephrectomy and 97 per cent for partial nephrectomy.
“Our research suggests that active surveillance of small kidney masses offers similar cancer outcomes to radical or partial surgery in the short and intermediate term” says Dr Patel.
“The results of this study support the need for a multicentre, prospective randomised trial to compare how active surveillance and surgery compare when it comes to managing such patients.”
Notes to editors
Active surveillance of small renal masses offers short-term oncological efficacy equivalent to radical and partial nephrectomy. Patel et al. BJUI. 110, pp1270. (November 2012). doi:10.1111/j.1464-410X.2012.11130.x
Established in 1929, BJUI is edited by Professor John Fitzpatrick from Mater Misericordiae University Hospital and University College Dublin, Ireland. It provides its international readership with invaluable practical information on all aspects of urology, including original and investigative articles and illustrated surgery. http://wileyonlinelibrary.com/journal/BJU
About Wiley. Founded in 1807, John Wiley & Sons, Inc. has been a valued source of information and understanding for more than 200 years, helping people around the world meet their needs and fulfill their aspirations. Wiley and its acquired companies have published the works of more than 450 Nobel laureates in all categories: literature, Economics, Physiology or Medicine, Physics, Chemistry, and Peace. Our core businesses publish scientific, technical, medical, and scholarly journals, encyclopedias, books, and online products and services; professional/trade books, subscription products, training materials, and online applications and Web sites; and educational materials for undergraduate and graduate students and lifelong learners. Wiley’s global headquarters are located in Hoboken, New Jersey, with operations in the U.S., Europe, Asia, Canada, and Australia.